Amgen Inc Investor Call At IASLC 2019 World Conference on Lung Cancer Transcript

Sep 08, 2019 / 03:00PM GMT
Operator

My name is Mary, and I will be your conference facilitator today for Amgen's call in conjunction with the World Conference on Lung Cancer. (Operator Instructions)

I would now like to introduce Arvind Sood, Vice President of Investor Relations. Mr. Sood, you may now begin.

Arvind Sood - Amgen Inc. - VP of IR

Thank you, Mary. So first, I would like to welcome all of you to our call this morning. For those in the United States, good morning; and for those in Barcelona, I wish I was there with you.

So we presented new clinical data today at the ongoing World Conference on Lung Cancer. This data is from our ongoing Phase I study evaluating AMG 510 in patients with previously treated KRAS G12C-mutated solid tumors. I'm joined this morning by our Head of R&D, Dr. David Reese, who will briefly highlight the breadth of our oncology portfolio and development; followed by Dr. Greg Friberg, who's our Vice President of Global Oncology Development. Greg will review the data on AMG 510 that was presented today in the scientific session. After Greg's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot